Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience Abstract #1764

Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.
Aim(s): To analyze the clinicopathological and molecular features of patients receiving TKI treatment, thus assessing toxicity and efficacy in our practice.
Materials and methods: Observational study. Period: January 2008 - May 2016. Statistical analysis: IBM SPSS Statistics 22.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Keywords: TNE, TKI

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1786 Targeted Therapies (TT) (Sunitinib and Everolimus) for Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). A Case Series
Introduction: Sunitinib (Sun) and Everolimus (Eve) are effective treatments for advanced GEP-NET. Lack of standard treatment sequencing and potential toxicities may preclude it´s use.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Juan Manuel O'Connor
Keywords: TNE, therapy target
#232 Prognostic Factors and Survival in 481 Patients with Pancreatic and Peripancreatic Endocrine Tumors: Results from the National Cancer Registry of Spain (RGETNE)
Introduction: Duodenopancreatic neuroendocrine tumors (NETs) are uncommon neoplasms with a wide spectrum of clinical presentation. The infrequent occurrence of these tumors makes large experiences very scarce.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Elena Martin-Perez
#557 The Role of Chemotherapy in the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The Large Experience of the Spanish National Tumor Registry (RGETNE)
Introduction: GEPNETs represent a heterogenous family of tumors of challenging clinical management. Treatment of advanced disease is evolving, including some recent relevant achievements with novel targeted agents. How to best integrate these new agents with conventional chemotherapy(CT) is still a matter of debate.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Rocio Garcia-Carbonero
Keywords: chemotherapy
#1926 Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE)
Introduction: RGETNE is a national hospital-based GEP-NENs registry coordinated by the Spanish multidisciplinary scientific society GETNE.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD-PhD Paula Jimenez Fonseca
#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Prof Rachel Riechelmann